Ascidian Therapeutics announced this week that the FDA has cleared its investigational new drug (IND) application and granted fast track designation...

In a recent study, researchers in Spain confirmed the feasibility of using CRISPR-Cas9 to correct pathogenic mutations in the ABCA4 gene in...